Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuvant Chemotherapy Scheme Customized by Levels of BRCA1 in Women With Primary HER2 Negative Breast Cancer (The BERNAQ Clinical Trial)
Overview
- Phase
- Phase 2
- Intervention
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
- Conditions
- Breast Cancer
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Enrollment
- 30
- Locations
- 7
- Primary Endpoint
- Rate of residual tumor types RCB-0 and RCB-I (good pathological response) at the time of surgery.
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain complete response of their primary tumor. BReast Cancer 1 (BRCA1) plays a crucial role in DNA repair and associations between BRCA1 mRNA expression and sensitivity to platinum and/or resistance to taxanes has been previously documented. We propose a two-arm, randomized, multi-centre, open-label phase II study to compare the efficacy and tolerability of NAC customized by BRCA 1 levels versus standard FEC chemotherapy, being pathological complete response the primary endpoint.
Detailed Description
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain complete response of their primary tumor.BReast Cancer 1 (BRCA1) plays a crucial role in DNA repair. Associations between BRCA1 mRNA expression and sensitivity to platinum and/or resistance to taxanes are previously documented. Improving complete response rates with NAC we can improve outcomes in breast cancer. If we establish biomarkers which predict better response we may optimized treatment by individualized breast cancer care. Therefore, we propose a two-arm, randomized, multi-centre, open-label phase II study. The study will compare the efficacy and tolerability of NAC customized by BRCA 1 levels versus standard chemotherapy, being pathological complete response the primary endpoint. Women with primary Her-2 negative breast cancer who have not undergone previous treatment for invasive breast cancer will be randomized to receive the following: Treatment Arm 1 (standard therapy): 5-Fluorouracil, Epirubicin and Cyclophosphamide day 1 every 3 weeks per three cycles; Treatment Arm 2: Patients with low levels of BRCA1 mRNA will receive Epirubicin and Cisplatin day 1 every 3 weeks and 5-Fluorouracil for three cycles; And patients with high levels of BRCA1 will receive docetaxel day 1 every three weeks per three cycles. Definitive surgery will be performed within 4 weeks after the last cycle.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female gender
- •18 years or older
- •Performance Status- ECOG: 0-1
- •Histologically confirmed invasive breast cancer
- •Primary tumor greater than 2 cm diameter
- •Any N (0-3)
- •No evidence of metastasis (M0), HER-2/ERBb2 negative.
- •Known hormone receptors status.
- •Haematopoietic status: Absolute neutrophil count \> 1.5 x 109/L; Platelet count \> 100 x 109/L
- •Hemoglobin at least 9 g/dl)
Exclusion Criteria
- •Received any prior treatment for primary invasive breast cancer.
- •Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated:
- •Basal and squamous cell carcinoma of the skin;Carcinoma in situ of the cervix.
- •Diagnosis of inflammatory breast cancer.
- •Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction uncontrolled hypertension (? 180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen.
- •Left Ventricular Ejection Fraction of \< 50% measured by echocardiography.
- •Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject?s safety.
- •Unresolved or unstable, serious adverse events from prior administration of another investigational drug.
- •Active or uncontrolled infection.
- •Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF.
Arms & Interventions
Standard FEC Regimen
Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Intervention: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
No or Low BRCA1 expression
Epirubicin + Cisplatin + Fluorouracil
Intervention: Epirubicin + Cisplatin + Fluorouracil
Normal or High BRCA1 expression
Docetaxel + Ciclofosfamide
Intervention: Docetaxel + Ciclofosfamide
Outcomes
Primary Outcomes
Rate of residual tumor types RCB-0 and RCB-I (good pathological response) at the time of surgery.
Time Frame: 4-8 weeks after the last neoadjuvant chemotherapy cycle.
To evaluate and compare the rate of good pathological response (residual tumor types RCB-0 and RCB-I) at the time of surgery in patients with ER or PgR positive, or triple negative (non-Her2/Erb 2 overexpressing and/or amplified) breast cancer randomized to standard neoadjuvant chemotherapy (NAC) based in anthracyclines versus customized NAC according levels of BRCA1 expression.
Secondary Outcomes
- Rates of residual tumor types RCB-0, RCB-I, RCB-II and RCB-III pathological response in surgical breast and axillary node resection specimens(4-8 weeks after the last neoadjuvant chemotherapy cycle .)
- Percentaje of patients candidates to breast conserving mastectomy as indicated by surgeon(At baseline and after the last neoadjuvant chemotherapy cycle (up to 24 weeks after randomization).)
- Percentaje of patients candidates to conventional mastectomy as indicated by surgeon(At baseline and after the last neoadjuvant chemotherapy cycle (up to 24 weeks after randomization).)
- Percentage of patients with negative axillary nodes(4-8 weeks after the last neoadjuvant chemotherapy cycle.)
- Complete tumoral response at the time of surgery (WHO criteria).(At baseline and after the last neoadjuvant chemotherapy cycle (up to 24 weeks after randomization).)
- Partial tumoral response at the time of surgery (WHO criteria).(At baseline and after the last neoadjuvant chemotherapy cycle (up to 24 weeks after randomization).)